| Outcome Measures: |
Primary: Change from baseline in Random blood sugar (RBS) and fasting blood sugar (FBS) levels at week 12 in participants receiving Vildagliptin combination with Metformin, To determine the efficacy of vildagliptin/metformin changes from baseline in random blood sugar (RBS) and fasting blood sugar (FBS) levels after 12 weeks of therapy. \[Designated as safety issue: No \], Week 12 | Secondary: Changes from baseline in HbA1c Levels at Week 12 in participants receiving Vildagliptin combination with Metformin, To determine the efficacy of vildagliptin/metformin changes from baseline in HbA1c levels after 12 weeks of therapy. \[ Designated as safety issue: No \], Week 12|Number of participants experiencing hypoglycemic episodes in the 12 weeks receiving Vildagliptin combination with Metformin., To evaluate the number of participants experiencing hypoglycemic episodes in the 12 weeks \[ Designated as safety issue: Yes \], Week 12|Number of participants who experienced an Adverse Event, To evaluate the number of participants who experienced an adverse event after 12 weeks of therapy. \[ Designated as safety issue: Yes \], 12 weeks
|
